Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT00001383 Completed - Breast Cancer Clinical Trials

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

Start date: March 1994
Phase: Phase 1
Study type: Interventional

This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel. Groups of 3 to 6 patients receive continuous-infusion paclitaxel for 5 days and oral PSC 833 for 6-7 days, following paclitaxel on the first course, then beginning 3 days prior to paclitaxel on subsequent courses. Stable and responding patients are re-treated every 21 days, with paclitaxel dose adjusted to maintain an absolute neutrophil count less than 500 for no more than 4 days.